404 related articles for article (PubMed ID: 12498958)
1. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
[TBL] [Abstract][Full Text] [Related]
2. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
4. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
5. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
6. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
7. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
8. Neuropathology in mice expressing human alpha-synuclein.
van der Putten H; Wiederhold KH; Probst A; Barbieri S; Mistl C; Danner S; Kauffmann S; Hofele K; Spooren WP; Ruegg MA; Lin S; Caroni P; Sommer B; Tolnay M; Bilbe G
J Neurosci; 2000 Aug; 20(16):6021-9. PubMed ID: 10934251
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Rathke-Hartlieb S; Kahle PJ; Neumann M; Ozmen L; Haid S; Okochi M; Haass C; Schulz JB
J Neurochem; 2001 May; 77(4):1181-4. PubMed ID: 11359883
[TBL] [Abstract][Full Text] [Related]
10. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.
Tofaris GK; Garcia Reitböck P; Humby T; Lambourne SL; O'Connell M; Ghetti B; Gossage H; Emson PC; Wilkinson LS; Goedert M; Spillantini MG
J Neurosci; 2006 Apr; 26(15):3942-50. PubMed ID: 16611810
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.
Zhou W; Schaack J; Zawada WM; Freed CR
Brain Res; 2002 Feb; 926(1-2):42-50. PubMed ID: 11814405
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
13. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
Klein RL; King MA; Hamby ME; Meyer EM
Hum Gene Ther; 2002 Mar; 13(5):605-12. PubMed ID: 11916484
[TBL] [Abstract][Full Text] [Related]
15. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Junn E; Mouradian MM
Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
17. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
Masliah E; Rockenstein E; Veinbergs I; Mallory M; Hashimoto M; Takeda A; Sagara Y; Sisk A; Mucke L
Science; 2000 Feb; 287(5456):1265-9. PubMed ID: 10678833
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
